Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by awol1on Jun 05, 2009 11:22am
388 Views
Post# 16046985

Merk settlement

Merk settlementfrom stockhouse... funny thing was, i sent an email to Dr. Calais last night asking if there was anything developing that would affect the share price in the future.  I was thinking of averaging down.  I didn't add any before this, was thinking of doing it today.  Would have been a double overnight if i had trusted my initial thoughts... yuck...

2009-06-05 08:45 ET - News Release

Dr. Philippe Calais reports

AMBRILIA SETTLES ITS ARBITRATION WITH MERCK

Ambrilia Biopharma Inc. has settled with Merck Sharp and Dohme Research Ltd. and Merck & Co. the arbitration pending before the International Court of Arbitration of the International Chamber of Commerce that concerned their exclusive licence agreement of Oct. 12, 2006, and a Nov. 14, 2003, confidentiality agreement. The terms of the settlement provide for the termination of the licence agreement and the confidentiality agreement that were a subject of the arbitration, resulting in the return to Ambrilia of its HIV/AIDS protease inhibitor (PI) program and licensed know-how and technology. This includes Ambrilia's lead compound, PPL-100, and related technology and compounds. The settlement agreement also provides for the payment by Merck to Ambrilia of an amount of $2-million (U.S.) within 10 business days of the settlement and a royalty for a period of 10 years from first commercial sale of a certain family of products, and the release of all claims made in the arbitration.

"With this settlement, the return of PPL-100 to Ambrilia strengthens our virology portfolio. We are now in a favourable situation to explore different strategic opportunities for our virology pipeline," said Dr. Philippe Calais, president and chief executive officer of Ambrilia.

We seek Safe Harbor.

Bullboard Posts